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Experimental Zika Virus Inoculation 
in a New World Monkey Model 
Reproduces Key Features of the 
Human Infection
Charles Y. Chiu  1,2,3, Claudia Sánchez-San Martín1,2, Jerome Bouquet1,2, Tony Li1,2, Shigeo 
Yagi4, Manasi Tamhankar5, Vida L. Hodara5, Laura M. Parodi5, Sneha Somasekar1,2, Guixia 
Yu1,2, Luis D. Giavedoni5, Suzette Tardif5 & Jean Patterson5
A monkey model of Zika virus (ZIKV) infection is urgently needed to better understand transmission 
and pathogenesis, given its proven association with fetal brain defects in pregnant women and acute 
neurological illness. Here we experimentally infected 4 male marmosets with ZIKV (prototype 1947 
African strain) and monitored them clinically with sampling of various body fluids and tissues for 
nearly 3 months. We show that the course of acute infection with ZIKV in these New World monkeys 
resembles the human illness in many respects, including (1) lack of apparent clinical symptoms in most 
cases, (2) persistence of the virus in body fluids such as semen and saliva for longer periods of time 
than in serum, and (3) generation of neutralizing antibodies as well as an antiviral immunological host 
response. Importantly, ZIKV-infected saliva samples (in addition to serum) were found to be infectious, 
suggesting potential capacity for viral transmission by the oral route. Re-challenge of a previously 
infected marmoset with a contemporary outbreak strain SPH2015 from Brazil resulted in continued 
protection against infection, no viral shedding, and boosting of the immune response. Given the key 
similarities to human infection, a marmoset model of ZIKV infection may be useful for testing of new 
drugs and vaccines.
Zika virus (ZIKV) is an infectious RNA flavivirus primarily transmitted to humans by the bites of Aedes spp. mos-
quitoes1,2. An outbreak of ZIKV began in Brazil in early 2015 and has since spread throughout South America, 
Central America, and the Caribbean, with autochthonous cases now being reported in the United States (Miami, 
Florida, and Texas). The rapid emergence of ZIKV in the Western Hemisphere is of particular concern given the 
proven association of viral infection with devastating fetal outcomes in pregnant women, including miscarriage 
and microcephaly3. Although the majority of ZIKV-infected individuals (~80%) are asymptomatic4, patients can 
present with a self-resolving acute illness consisting of fever, conjunctivitis, rash, and joint pain. Rarely, ZIKV 
has also been associated with neurological complications such as meningoencephalitis5 and Guillain-Barré 
syndrome6.
Although the primary mode of ZIKV transmission is via mosquito bite, it has also been shown that the virus 
has the capacity for sexual transmission7. Following an acute infectious episode, the virus can reside in semen for 
at least 3 months8. The virus has also been detected for at least 2 weeks after symptom onset in saliva and urine 
samples from acutely infected individuals9, although it is unknown whether the sampled body fluids were infec-
tious. ZIKV transmission by blood transfusion from an infected donor has also been reported10.
To date, there have been several published mouse models of ZIKV infection; however, these have focused on 
studying ZIKV-associated complications in pregnant females such as fetal microcephaly11–14, and have required 
the use of immunodeficient animals with defects in interferon-related signaling pathways, likely due to absence of 
STAT2 cytokine inhibition of ZIKV in mice2. A viable non-human primate (NHP) model may thus better reflect 
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the biology and pathogenesis of ZIKV in acute human infections. Investigations with NHP can also enable serial 
sampling and analyses of body fluids (e.g. urine, saliva, feces, and semen) that are impractical with rodent models.
Rhesus and cynomolgus macaque models of ZIKV infection are currently in development15–26. However, there 
are compelling reasons to consider the common marmoset (Callithrix jacchus), a New World monkey, as a useful 
alternative candidate model for ZIKV investigation. Common marmosets are known to have a high susceptibility 
to infection by a variety of pathogenic outbreak agents27, including Ebola virus28, Lassa virus29, and titi monkey 
adenovirus − a virus found to be associated with cross-species transmission to both monkeys and humans30. 
Related flaviviruses to ZIKV, including dengue virus (DENV) and West Nile virus (WNV) are known to cause 
productive infections in marmosets31,32. Furthermore, the recent detection of ZIKV in serum or saliva from wild 
marmosets from Brazil (26.7%, 4 of 15 animals tested)33 suggests that marmosets are a potential reservoir for 
maintaining Zika virus in endemic countries.
Here we present a marmoset model of acute ZIKV infection generated by inoculating 4 animals with ZIKV, 
followed by clinical monitoring and serial sampling for nearly 3 months. We sought to evaluate ZIKV infectivity, 
pathogenesis, persistence in infected body fluids and potential transmission risk, and production of neutralizing 
antibodies. The host response to acute ZIKV infection was also investigated by lymphocyte phenotyping, cytokine 
analyses and global transcriptome profiling of blood from experimentally infected animals.
Methods
Animal Ethics Statement. All animal studies were conducted at the Southwest National Primate Research 
Center (SNPRC), Texas Biomedical Research Institute (TBRI); molecular, viral, and transcriptome analyses 
of marmoset body fluids and tissues were conducted at University of California, San Francisco (UCSF). TBRI 
is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
International and operates in accordance with the NIH and U.S. Department of Agriculture guidelines and 
the Animal Welfare Act. The Institutional Animal Care and Use Committee (IACUC) and the Institutional 
Biohazards Committee (IBC) of the TBRI approved all marmoset experiments related to this study. All experi-
ments were performed in accordance with relevant guidelines and regulations.
Marmosets were kept healthy and well-nourished with strict feeding protocols and close monitoring of their 
health status prior to the start of the study and during the entire study period. One week before inoculation, 
animals were transferred to the biosafety level-2 facility at the SNPRC and housed individually in cages specif-
ically developed for marmoset work. As they are social animals in the wild, all marmosets had auditory, visual, 
and olfactory access to each other throughout the study. Marmosets were sedated and humanely euthanized by 
administration of a sodium pentobarbital solution by a licensed veterinarian at the TBRI.
ZIKV propagation in cell culture. Vero cells were inoculated with the 1947 Uganda strain of ZIKV (pas-
saged 147X in mouse brain and 3X in Vero cells) in the African lineage, which has been maintained at the Viral 
and Rickettsial Disease Laboratory (VRDL) branch of the California Department of Public Health. Viral superna-
tants for cell culture passaging and the generation of infectious stocks were subjected to 3 freeze-thaw cycles and 
clarified by centrifugation for 10 min × 4000 g. After cells achieved 80–90% confluency, cell culture media were 
changed to maintenance media with 2% FBS and were inoculated with 100 µL of passaged viral supernatant. Viral 
replication was monitored over 14 days by visual inspection under light microscopy for cytopathic effect (CPE).
Experimental ZIKV infection of marmosets. Four healthy adult male marmosets, averaging 2.1 years of 
age (range: 2.0–2.3 years) and 391.7 g (range: 332–453 g), were inoculated intramuscularly with 0.1 mL of a 1 × 105 
pfu/mL culture of the 1947 Uganda African lineage of ZIKV. Samples from an additional 4 male marmosets were 
used as matched controls for performing comparative gene expression studies by transcriptome profiling. All 
study marmosets were pre-screened for ZIKV antibody by neutralization and were found to be negative.
Animals were monitored daily for signs of clinical illness, with generalized sickness defined as a score of >4 
(Supplementary Table 1). Specific monitoring was conducted for signs associated with ZIKV infection in humans, 
including rash, anorexia, conjunctivitis, diarrhea, malaise, and postural abnormalities associated with joint or 
head pain. Samples were collected from restrained, unsedated animals at predetermined time intervals. Animals 
were restrained for less than 10 minutes in a device specifically designed for short-term restraint of marmosets for 
sample collection purposes. For the 4 male marmosets, blood samples were collected via venipuncture on days 
1, 3, 6, 9 and 28; voided urine and feces were collected on days 3, 5, 7, 9, 11, and 13; saliva was collected on days 
3, 6, 9, and 14 by allowing the subjects to chew on a sterile cotton swab; semen samples were collected on days 9, 
14, 28 by vibratory stimulation of the penis, using a modified FertiCareTN medical vibrator unit (Multicept A/S, 
Denmark) (Fig. 1). Whole blood was collected in tubes containing RNA stabilization media (Biomatrica, Inc.) for 
transcriptome analysis. At day 28, 2 of the 4 male marmosets were randomly selected to be euthanized and their 
necropsy tissues examined for persistent ZIKV infection. The remaining two inoculated male marmosets were 
observed for an additional 7 weeks, with samples collected at weeks 7, 10 and/or 11 to evaluate long-term ZIKV 
persistence in body fluids. One of the remaining male marmosets was re-challenged with 0.25 ml of a 1 × 106 pfu/
mL culture of Brazilian ZIKV strain SPH201534 12 months after the first inoculation and followed clinically with 
serial sample collection until necropsy at day 56 (Supplementary Table 2).
Measurement of infectious ZIKV titers by plaque assay. Plaque titration for quantification of infec-
tious ZIKV was performed using Vero cells. 100 µL of serially dilutions of ZIKV from 10−1 to 10−5 was added to 
duplicate wells of 6-well plates containing a confluent monolayer of Vero cells, followed by incubation at 37 °C 
for 1 hr for adsorption. After adsorption, each well was overlaid with 2X Eagle’s Minimum Essential Medium in 
Earle’s balanced salt solution with 4% heat-inactivated FBS and 1.2% (w/v) Oxoid purified agar in water in a 1:1 
ratio. The plates were maintained at 37 °C, 5% CO2 for 3 days, followed by 2nd overlay with the same 2x medium 
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with 0.08% neutral red and 2% Oxoid purified agar and in water in a 1:1 ratio. The 2nd day after 2nd overlay, 
plaques were counted and calculated in plaque forming units per mL (PFU/mL).
Measurement of ZIKV RNA loads by quantitative RT-PCR. The course of infection in inoculated ani-
mals was monitored by determination of ZIKV RNA loads (expressed as RNA copies/mL) in serum, urine, saliva, 
stool, semen (collected in a conical tube at the time of ejaculation), and semen swabs (semen swabbed off of the 
penis and surrounding tissues immediately following ejaculation). Estimated ZIKV RNA loads were calculated 
by generation of a standard curve, followed by quantitative RT-PCR testing for 45 cycles using primers targeting 
the envelope gene (ZIKV-1086/ZIKV-1162)35. By standard curve analysis, the estimated limit of detection for the 
qRT-PCR assay is ~15 RNA copies/mL).
ZIKV serological analysis by antibody neutralization. Plaque-reduction neutralization testing 
(PRNT) on longitudinally collected marmoset sera was performed by the California Department of Public 
Health. The protocol was similar to that used by the US CDC for confirmatory ZIKV testing in patients36. Briefly, 
100 plaque forming units (PFU) of ZIKV (1947 Uganda strain or 2015 Brazilian SPH2015 strain, depending on 
the strain that was inoculated) were mixed with equal volumes of serial 2-fold dilutions of inactivated marmoset 
sera and incubated for 1 hr at 36 °C, followed by inoculation and adsorbing to a monolayer culture of Vero cells 
for 1 hr at 36 °C. After addition of 3 mL of 1% agar in Eagle’s Minimal Essential Medium (MEM), plates were 
Figure 1. Study design and neutralizing antibody testing. (A) After intramuscular inoculation of ZIKV at day 
0, samples (serum, stool, urine, saliva, and semen) are collected at predesignated time points. (B) Longitudinally 
collected serum samples from inoculated marmosets were tested at predesignated time points for ZIKV-specific 
neutralizing antibodies using a PRNT (plaque reduction neutralization test). The antibody titer as determined 
by PRNT at a given time point is shown below the icon. Three of the 5 marmosets were sacrificed after 
approximately 1 month (denoted by a red “X”) to assess viral persistence in tissues.
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placed in a 36 °C, 5% CO2 incubator ×3 days, followed by addition of 3 mL of 1% agar and 0.004% neutral red in 
Eagle’s MEM and another 1–2 days of incubation until plaques were formed. An 80% reduction of the number of 
plaques compared to positive control wells inoculated with virus-diluent mixtures was considered neutralization, 
with serum titers reported as the highest dilution exhibiting ≥80% reduction.
Histology of ZIKV-infected marmosets. Samples of aseptically removed tissues were fixed in 10% neu-
tral buffered formalin and embedded in paraffin for histology. Paraffin-embedded tissues were cut in 5 µm sec-
tions, de-paraffinized, and stained with hematoxylin and eosin (H&E) prior to visualization by light microscopy. 
Additional samples were freshly frozen in liquid nitrogen and kept stored in a −80 °C freezer until analyzed. Two 
board-certified veterinary pathologists independently evaluated the histologic sections.
Lymphocyte phenotyping. Phenotypic characterization of marmoset peripheral blood mononuclear cells 
(PBMCs) was performed by multicolor flow cytometry using direct immunofluorescence. Aliquots of 100 μl 
of EDTA whole blood were directly incubated with antibodies for 20 minutes at room temperature; red blood 
cells were lysed with ammonium-chloride-potassium (ACK) buffer, and cells were then washed twice with 
phosphate-buffered saline (PBS) and fixed with 1.6% methanol-free formaldehyde before analysis in a CyAn 
ADP flow cytometer (Beckman-Coulter). The antibodies used for this analysis were conjugated to fluorescein iso-
thiocyanate (FITC), Phycoerythrin (PE), Peridinin-chlorophyll-cyanin 5.5 (PerCP-Cy5.5), Phycoerythrin-cyanin 
5.1 (PC5), Phycoerythrin-cyanin 7 (PC7), Pacific Blue, BD Horizon V500, Allophycocyanin (APC) or Alexa 
Fluor 700. Antibodies included in this study were: CD3 (clone SP34.2), CD4 (clone L200) and HLA-DR (clone 
G46.6/L243) from BD-Biosciences; CD14 (clone 322A-1 (My4), CD159a (NKG2A; clone Z199), CD20 (clone 
H299(B1)), CD335 (NKp46; clone BAB281) and CD337 (NKp30; clone Z25) from Beckman-Coulter; CD16 
(clone 3G8), CD8 (clone HIT8a), CD86 (clone IT2.2) from Biolegend; and CD159c (NKG2C;clone 134522) from 
R&D Systems.
For analyses, lymphocytes were gated based on their characteristic forward and side scatter pattern, followed 
by T-cell selection using a second gate on the CD3-positive population. Thus, CD8 T cells were defined as CD8+/
CD3+ and CD4 T cells as CD4+/CD3+. Natural Killer cells (NK) were defined as CD3−/CD20−/CD14− and 
analyzed by the expression of NK cell markers CD16+, CD8, NKG2A, NKG2C, NKp30 and NKp46. B cells were 
defined as CD20+/CD3−/CD14−.
Multiplex cytokine analysis of plasma. Plasma samples were analyzed for marmoset cytokines and 
chemokines on the Luminex 100 system (Luminex) using established protocols for New World primates37. 
The assay included evaluation of the following 21 analytes: GRO-α (CXCL1), interferon alpha (IFN-α), IFN-γ, 
interleukin-1 beta (IL-1β), IL-1 receptor antagonist (IL-1RA), IL-4, IL-8, IL-10, IL-12 p70, IL-15, IL-18, IL-22, 
monocyte chemoattractant protein 1 (MCP-1, CCL2), macrophage migration inhibitory factor (MIF), monokine 
induced by gamma interferon (MIG, CXCL9), macrophage inflammatory protein 1-alpha (MIP-1α, CCL3), 
MIP-1β (CCL4), regulated on activation, normal T cell expressed and secreted (RANTES, CCL5), tumor necrosis 
factor-alpha (TNF-α), soluble CD40 ligand (sCD40L), soluble intercellular adhesion molecule 1 (sICAM-1), and 
vascular endothelial growth factor A (VEGF-A).
Transcriptome analysis. Four age-/sex-matched healthy marmosets were used as controls for the tran-
scriptome analysis. All marmosets studied here were from a single colony, thus increasing genetic similarities 
and decreasing environmental bias. Technical bias in the whole transcriptome analysis was not observed by PCA 
(Supplementary Fig. 1).
Four hundred microliters of blood were drawn directly into RNAgard tubes (Biomatrica) for immediate 
RNA stabilization of intracellular RNA at collection. Total RNA was extracted using the Biomatrica Blood RNA 
Purification Kit (Biomatrica). The Ovation Human Blood RNA-Seq Kit (Nugen) was used to generate RNA-seq 
libraries from 100 ng of input per sample (as measured using the Invitrogen Qubit RNA HS Assay Kit) according 
to the manufacturer’s protocol. Libraries were sequenced as 100 base pair (bp) paired-end runs on a HiSeq 2500 
instrument (Illumina).
Paired-end reads were mapped to the marmoset genome (Callithrix jacchus Ensembl version 3.2.1), using 
STAR 2.538, and gene and transcript normalized counts were calculated by HTSeq version 0.6.039. Differential 
expression of genes was calculated using linear modeling using the Bioconductor EdgeR software package version 
3.12.240 implemented in the R programming language. Genes were considered to be differentially expressed when 
their fold change was >±2, p-value <0.05, and adjusted p-value (or false discovery rate, FDR) < 0.1%. Pathway 
and network analyses of the transcriptome data were performed using Ingenuity Pathway Analysis (IPA) software 
(Qiagen).
Data Availibility. Marmoset transcriptome data has been submitted to the public National Center 
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) repository (accession number 
PRJNA315767).
Results
Experimental infection of marmosets with ZIKV. To investigate ZIKV infectivity in marmosets, 
and potential pathogenesis and persistence of virus in body fluids, including semen, we inoculated 4 healthy 
male marmosets intramuscularly with  0.25 mL of 106 plaque-forming units (PFUs) of the 1947 Uganda proto-
type ZIKV strain MR766. The inoculation dose was chosen to be physiologic, comparable to the typical high-
est observed serum titers in patients with acute ZIKV infection41. Marmosets remained largely asymptomatic 
during the entire study period, with the exception of one male marmoset that exhibited drowsiness 2 days 
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post-inoculation and had lost 7% of its body weight by day 5. However, this animal subsequently appeared alert 
and active and ate normally. No animal ever displayed a clinical score of > = 4, indicative of acute sickness, at 
any time during the study (Supplementary Table 1). Specifically, none of the other inoculated animals displayed 
anorexia, activity changes, or weight loss, and no subjects had fever, rash, conjunctivitis, diarrhea, or postural 
abnormalities suggestive of joint and/or muscle pain.
ZIKV RNA in body fluids from experimentally infected marmosets. Serum, saliva, and urine samples 
were collected longitudinally at predesignated intervals (see Methods) for up to 14 days following inoculation. RNA 
loads of ZIKV (copies/mL) were estimated using quantitative ZIKV RT-PCR (Figs 1A, 2 Supplementary Table 2). 
A rapid rise and fall in ZIKV RNA, beginning at day 1 and returning to zero within 7–9 days, was observed in sera 
from all 4 inoculated male marmosets. Peak viremia was >105 copies/ml at day 3 post-inoculation. In contrast to 
serum, ZIKV RNA loads in urine and saliva rose at later time points but persisted for longer periods of time, with 
peak viral production comparable to those observed in serum. Notably, at the end of the ~14 day collection period, 3 
of 4 male marmosets (75%) and 2 of 4 (50%) were still shedding virus in the urine and saliva, respectively. Virus was 
also detected in the feces of inoculated animals beginning on day 5, albeit at much lower titers (102–103 copies/ml), 
and one animal (25%) continued to shed virus at day 13. ZIKV was also sporadically detected in semen and semen 
swabs in some, but not all, animals at a low level during the first 2 weeks following inoculation.
A ZIKV antibody neutralization assay by plaque reduction neutralization testing (PRNT), validated at the 
California Department of Public Health, was used to screen all experimentally infected marmosets for the devel-
opment of neutralizing antibodies (Abs) to ZIKV (Fig. 1B). Importantly, all 4 male marmosets had negative 
pre-inoculation Ab titers of <1:10. Borderline ZIKV neutralizing antibody responses were detected in all 4 ani-
mals at a titer of 1:10 by day 6 post-inoculation, and positive titers ranging from 1:80–1:320 after week 4.
Figure 2. Viral loads in body fluids after acute ZIKV infection. The ZIKV load in copies per milliliter is plotted 
according to day post-inoculation. The line graph corresponding to each marmoset is displayed in a distinct 
color. Note that some lines are not visible in the serum graph due to similar viral load measurements that result 
in overlapping plots.
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Gross pathology and histology in ZIKV-infected marmosets. Two of the 4 male marmosets were 
euthanized at day 28 post-inoculation, respectively (Fig. 1B), for analysis of ZIKV pathology and persistence 
in tissues. No significant gross pathological lesions were observed in any of the post-mortem tissues. Salient 
histologic findings include mild-moderate nephropathy and vacuolization in hepatocytes associated with gly-
cogen storage in the 2 euthanized animals. These histologic findings are common in healthy marmosets from 
this colony.
ZIKV persistence in tissues and body fluids from experimentally infected marmosets. From 
the 2 male euthanized marmosets, nearly all of the necropsy tissues were negative for ZIKV by qRT-PCR, with 
the exception of detectable virus in lymph node tissue (3,680 copies/mg) from 1 male. To evaluate long-term per-
sistence in body fluids, we also collected semen (6 and 10 weeks), semen swab (day 42), serum (6 and 10 weeks), 
urine (10 weeks), and saliva (11 weeks) from the 2 remaining marmosets. None of the samples collected after 6 
weeks were positive for ZIKV by qRT-PCR.
Viral infectivity from serum, saliva, and urine. Next, we sought to determine whether detected virus in 
body fluid compartments (e.g. serum, saliva, and urine) was infectious. We inoculated Vero cells with available 
ZIKV RT-PCR positive body fluids from infected male marmosets with RNA loads of 3.4 × 102 to 1.9 × 105 copies 
(Table 1). Viral cytopathic effect was observed after inoculation of 4 of 4 day 3 serum samples (each collected from 
an individual marmoset), and 4 of 4 day 7 saliva samples, but not from urine samples or day 14 semen samples.
Cytokine and lymphocyte analyses. Flow cytometry analysis of circulating lymphocytes in 
ZIKV-infected male marmosets showed no major changes for most of the lymphocyte subsets that were stud-
ied, including levels of T cells or CD8 T cells (Fig. 3A). However, we did observe an increase in the population 
of NKG2A + NK cells, which peaked by days 7–9 post-infection and returned to pre-infection levels by day 28 
post-infection. There were also detectable increases in the levels of the NK activation markers NKp30 and NKp46 
(data not shown). Interestingly, there was also a continuous up-regulation of the activation markers CD86 and 
HLA-DR on B cells during this acute period, returning to pre-infection levels by day 28 post-infection.
In parallel, we determined the plasma levels of 21 cytokines and chemokines with a validated Luminex assay37. 
The majority of these molecules were either below the limit of detection of the assay or did not change in a signif-
icant way after challenge with ZIKV (Supplementary Table 3). However, there was an increase over time in circu-
lating IFN-γ and MIG (CXCL9, a monokine induced by IFN-γ), both members of the type II interferon signaling 
pathway, which peaked between days 3 and 9 post-infection, and returned to basal levels by day 28 post-infection 
(Fig. 3B). In contrast, circulating levels of IFN-α, representative of the antiviral type I interferon response, were 
always below the limit of detection (Supplementary Table 3).
Whole transcriptome data analysis. The 4 asymptomatic ZIKV-infected male marmosets were sampled 
for whole blood transcriptome analysis at days 1, 3, 7, and 9 after post-infection, and were compared to 4 healthy 
uninfected male marmosets as controls. Two of the marmosets were followed up for 24 days post-infection 
and the remaining two marmosets were continually followed up for 42 and 64 days post-infection. The average 
Primate ID
Collection day 
post-infection Sample type
Volume of 
inoculum (μL)
Viral RNA copies 
of inoculum
Passage 
number
CPE 
present*
RT-PCR [Ct] of 
culture supernatant
1 3 saliva 100 1.24E + 03 0 ++  + [24.0]
1 3 serum 20 4.10E + 03 0 ++  + [18.3]
2 3 serum 20 2.08E + 03 0 ++  + [18.1]
3 3 serum 20 4.14E + 03 0 ++  + [19.4]
4 3 serum 20 4.00E + 03 0 ++  + [18.0]
1 7 saliva 100 3.88E + 04 0 ++  + [18.2]
2 7 saliva 100 1.41E + 03 0 ++  + [21.7]
3 7 saliva 100 1.92E + 02 0 ++  + [22.8]
4 7 saliva 100 2.40E + 03 0 ++  + [24.2]
4 7 urine 200 1.92E + 04 1# — —
1 13 urine 200 7.52E + 02 1# — —
4 13 urine 200 7.08E + 03 1# — —
1 14 saliva 200 6.86E + 01 0 — —
4 14 saliva 200 1.57E + 03 0 — —
4 14 semen 400 1.91E + 03 0 — —
4 14 semen swab 400 5.60E + 02 0 — —
Table 1. Cell culture of ZIKV from infected body fluids. Abbreviations: CPE, cytopathic effect; RT-PCR, 
reverse-transcriptase polymerase chain reaction; Ct, cycle threshold. * −, no CPE, +, mild-moderate CPE 
(<0–25%), ++, heavy CPE (>25%), reported from duplicate wells; cells were monitored daily for up to 14 days 
or until CPE was observed #atypical cytotoxicity observed at passage 0, so cell culture supernatants passaged 
once in Vero cells.
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sequencing depth was 25.0 M reads per sample (±13.9 M reads) (Supplementary Fig. 2). STAR/Cufflinks detected 
an average of 51.2% (±9.9%) of all Ensembl isoforms in each sample.
We examined whether there were any differentially expressed genes (DEGs) between the Zika-infected male 
marmosets at 1, 3, 7, 9, 42, and 64 days after post-infection and controls from their whole blood samples. For 
the first day post-infection (D1), 3 DEGs were found comparing Zika-infected against uninfected marmosets 
(Table 2). Three days post-infection (D3), 20 DEGs were found between the Zika-infected marmosets and con-
trols, with 90% (n = 18) up-regulated and 10% down-regulated (n = 2). At seven days post-infection (D7), the 
difference in gene expression increased relative to the controls, with 43 DEGs found, 95% (n = 41) up-regulated 
and 5% (n = 2) down-regulated. By nine days post-infection (D9), 1,049 DEGs were found, with 67% (n = 706) 
up-regulated and 33% (n = 343) down-regulated. Two animals were sacrificed after day 9, and only 2 marmosets 
remained for follow up at day 42 and 64 post-infection, with 12 and 20 DEGs found respectively, but significance 
is uncertain given the low number of replicates.
Gene ontology analysis revealed that 12 DEGs were shared between days 3, 7, and 9 in ZIKV-infected ver-
sus uninfected marmosets (Supplementary Table 4). All of the 12 DEGs were up-regulated, and there was 
Figure 3. Changes in lymphocyte subsets and circulating cytokines after acute ZIKV infection. (A) 
Polychromatic flow cytometry was used to identify T cells (upper left), CD8 T cells (upper right), NKG2A + NK 
cells (lower left), and CD20 + B cells expressing activation markers CD86 and HLA-DR (lower right). (B) 
Increases in protein expression of interferon-gamma (IFN-γ) and monokine induced by IFN-γ (MIG) were 
detected using a Luminex assay.
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an enrichment of terms related to the defense response to virus (GO:0051607), innate immune response 
(GO:0045087), and negative regulation of viral genome replication (GO:0045071). Notably, 6 of the 12 DEGs 
(MX1, MX2, ISG15, OAS2, OAS3, and GP2) were members of the type I interferon signaling pathway, whereas 
1 DEG (GBP1) was a member of the type II interferon signaling pathway. Only one DEG, U3, a small nucleolar 
RNA, was shared among all sampled time points (1, 3, 7, 9, 42, and 64 days post-infection).
Canonical pathway analysis showed that the interferon signaling pathway, which regulates host resistance against 
viral infections, was the only pathway significantly up-regulated at all sampling time points: 3 (n = 20 pathways), 7 
(n = 22 pathways), and 9 (n = 53 pathways) post-infection (Fig. 4). The type I interferon pathway was activated at 
days 3, 7 and 9, and type II interferon pathway was activated at day 9 (Supplementary Fig. 3). Pathways related to cell 
activation, including eIF2 signaling, actin-based motility by Rho family, and RhoA signaling pathways, were found 
to be significantly up-regulated only at D9. Pathway analysis at days 42 and 64 post-infection was attempted, but no 
pathway with significant up- or down-regulation could be predicted (data not shown).
Rechallenge of a male marmoset with a contemporary Brazilian strain of ZIKV. To assess 
ZIKV infection after rechallenge with a different strain, we used the contemporary Brazilian SPH2015 strain 
to re-inoculate a male marmoset previously infected with the prototype 1947 Uganda strain. The marmoset 
remained asymptomatic, and all body fluid samples collected after infection, as well as post-necropsy tissues from 
organs, were negative for ZIKV by qRT-PCR (Supplementary Table 2). The baseline positive ZIKV Ab titer was 
1:160 prior to and up to day 3 after rechallenge, but rose to >1:2560 by day 7.
Comparison Total DEGs Up-regulated Down-regulated
Day 1 versus uninfected 3 1 2
Day 3 versus uninfected 20 18 2
Day 7 versus uninfected 43 41 2
Day 9 versus uninfected 1049 706 343
Day 42 versus uninfected 12 5 7
Day 64 versus uninfected 20 9 11
Zika (all time points) versus uninfected 6 3 3
Table 2. Number of differentially expressed genes (DEG) between ZIKV-infected and uninfected marmosets by 
day post-inoculation.
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Figure 4. Top 10 canonical pathways associated with acute ZIKV infection by transcriptome profiling. 
Shown are the top 10 pathways at days 3, 7, and 9 post-inoculation, ranked by the negative log of the P-value 
of the enrichment score. The color scheme is based on Z-scores, with activation in orange and undetermined 
directionality in gray.
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Discussion
In this study, we found that male marmosets inoculated with ZIKV did not develop signs of clinical illness, mim-
icking the approximately 80% of human infections that are asymptomatic4. Other features resembling human 
infections are (1) a brief period of viremia (<1 week), (2) persistent detectable ZIKV RNA in saliva and urine for 
at least 2 weeks following infection, and (3) sporadic detection in semen and stool. We also show that immunity 
elicited by the prototype 1947 Uganda strain (MR766) protects against subsequent infection with a contemporary 
outbreak strain (2015SPH). Taken together, these results indicate that the ZIKV marmoset model mimics impor-
tant aspects of the human infection.
In ZIKV-infected marmosets, peak viral RNA loads in saliva and urine were comparable to those observed 
in serum, consistent with what has been previously documented in humans. Incorporation of these additional 
sample types is now part of many diagnostic and public health surveillance efforts. It is notable that ZIKV per-
sistence in saliva and urine, unlike in blood, was not uniform, despite the fact that the marmosets were derived 
from a closed colony suggesting a population that was relatively homogeneous genetically. Thus, host and perhaps 
environmental factors likely play a role in determining the degree of ZIKV shedding in a particular individual, 
as has been shown for patients with acute ZIKV infection42,43. In 2 of the 3 marmosets that were euthanized after 
1 month, we also found evidence of ZIKV persistence in lymph node tissue. Interestingly, acute ZIKV infection 
associated with lymphadenopathy has been described44, and viral persistence has been also shown in lymph 
nodes and cerebrospinal fluid samples from ZIKV-infected rhesus monkeys17.
Viruses isolated from serum and saliva samples from 4 of 4 ZIKV-infected male marmosets were capable 
of growth in cell culture, suggesting that these body fluids were potentially infectious. The possibility for ZIKV 
transmission through deep kissing has been raised in a recent case report describing sexual transmission of 
ZIKV45. However, although ZIKV has been detected in saliva9,42, no cases of human transmission through saliva 
have been documented to date. The male marmoset rechallenged with a contemporary strain of ZIKV did not 
show any evidence of active viral replication by qRT-PCR testing of serially collected body fluids and necropsy 
tissues. These results suggest that immunity elicited by the initial inoculation protected against subsequent infec-
tion; similar protection has been previously reported in a rhesus macaque model18. Notably, a marked increase in 
antibody titers was observed (from 1:160 to >1:2560) after rechallenge, suggesting non-sterilizing immunity and/
or a secondary anamnestic response to ZIKV rechallenge.
We found by transcriptome profiling that ZIKV infection induces significant up-regulation of the type I inter-
feron pathway at days 3, 7, and 9 post-infection (and the type II interferon pathway at day 9). However, parallel 
cytokine data show increases in protein expression of type II interferons (IFN-γ and MIG) and not type I at days 
3, 7, and 9. ZIKV is known to inhibit the type I interferon pathway in human cells (but not mouse) by inducing 
STAT2 degradation by the proteasome2. Consistent with this report, we observed productive ZIKV infections of 
marmosets and up-regulation of both type I and II interferon signaling, but an increase in only type II interferon 
protein expression. It is possible that suppression of the type I interferon-related antiviral response in ZIKV infec-
tion in humans and non-human primates is rescued by type II interferon pathways.
Our study design used the prototype 1947 Uganda strain instead of the 2015 contemporary Brazilian strain. 
However, prior studies comparing the two have found that infection characteristics in rhesus macaques are sim-
ilar18,20, and that the prototype 1947 Uganda strain is, similar to contemporary ZIKV strains, neurotropic and 
interferes with neurodevelopment46. Although less commonly used in biomedical research in the United States, 
the small size of marmosets does offer advantages in terms of easier housing and handling and decreased volume 
requirement for testing novel vaccines or therapeutics28. Surveillance data in wild marmosets also reveal that 
these monkeys may constitute a stable reservoir for the virus in the wild33, indicating that further investigations 
in this NHP model may have both clinical and public health relevance.
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